<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605734</url>
  </required_header>
  <id_info>
    <org_study_id>ShandongCHI-002</org_study_id>
    <nct_id>NCT01605734</nct_id>
  </id_info>
  <brief_title>TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>Phase II Trail of TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TACE is widely used in patients with unresectable HCC. However, it is a non-curative&#xD;
      approach; thus ,strategies to further improve the survival of these patients are needed.&#xD;
      Sorafenib is regarded as standard treatment for advanced HCC. It is the first systemic&#xD;
      therapy to demonstrate a significant survival benefit in HCC patients.The hypothesis is that&#xD;
      the combination of TACE with sorafenib could improve the survival of patients with&#xD;
      unresectable HCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>1 year</time_frame>
    <description>Time to progression is defined as time from randomization to radiological progression and will be evaluated every 8 week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FACT-Hep</measure>
    <time_frame>six months</time_frame>
    <description>FACT-Hep is a chart established to evaluate the life quality of patients with HCC every 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>six months after TACE</time_frame>
    <description>CR+PR+SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>six months</time_frame>
    <description>Number of participants with adverse events as a measure of safety and tolerability(According to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS and OS</measure>
    <time_frame>two years</time_frame>
    <description>The overall survival is defined as time from randomization to death due to any cause, and will be evaluated every 8 weeks in the protocol treatment, and every one year in the follow-up period,respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of TACE sessions and the interval time between two TACE sessions</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AFP</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>PHENYTOIN/SORAFENIB [VA Drug Interaction]</condition>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Group TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TACE will be carried out with chemotherapeutic agents and lipiodol; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated if clinically indicated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.</description>
    <arm_group_label>Group TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib combined with TACE</intervention_name>
    <description>All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study</description>
    <arm_group_label>Group Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients newly diagnosed as HCC according to European Association for Study of the&#xD;
             Liver criteria.&#xD;
&#xD;
          -  BCLC stage B or C&#xD;
&#xD;
          -  Child-Pugh class score≤8&#xD;
&#xD;
          -  ECOG performance status ≤2&#xD;
&#xD;
          -  Etiology: Hepatitis B virus(HBV) infection&#xD;
&#xD;
          -  Written informed consent (approved by the Institutional Review Board [IRB]obtained&#xD;
             prior to any study specific screening procedures&#xD;
&#xD;
          -  Patient must be able to comply with the protocol&#xD;
&#xD;
          -  Age 18-75 years&#xD;
&#xD;
          -  Haematology:Absolute neutrophil count (ANC) &gt; 1.5 x 109/L, Platelet count &gt; 50 x&#xD;
             109/L, Haemoglobin &gt; 9 g/dL (may be transfused to maintain or exceed this level)&#xD;
             Prothrombin time international normalized ratio &lt; 1.5&#xD;
&#xD;
          -  Biochemistry:Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)&lt; 5 x&#xD;
             the upper limit of normal,Total bilirubin &lt; 3 x the upper limit of normal,Serum&#xD;
             creatinine &lt; 1.5 x the upper limit of normal,Cholinesterase&gt;0.5x the lower limit of&#xD;
             normal，Prealbumin&gt;0.5x the lower limit of normal.&#xD;
&#xD;
          -  Life expectancy of &gt; 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BCLC stage D&#xD;
&#xD;
          -  Child-Pugh Score≥9&#xD;
&#xD;
          -  Clinically severe gastrointestinal bleeding within 4 weeks of the start of treatment&#xD;
&#xD;
          -  Preexisting or history of hepatic encephalopathy&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
&#xD;
          -  Pregnancy (positive serum pregnancy test) or lactation&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Currently or recent (within the 30 days prior to starting study treatment) treatment&#xD;
             of another investigational drug or participation in another investigational study&#xD;
&#xD;
          -  Clinically significant (i.e. active) cardiovascular disease for example&#xD;
             cerebrovascular accidents ( ≤ 6 months prior to study entry), myocardial infarction (&#xD;
             ≤ 6 months prior to study entry), unstable angina, New York Heart Association (NYHA)&#xD;
             grade II or greater congestive heart failure, serious cardiac arrhythmia requiring&#xD;
             medication&#xD;
&#xD;
          -  Evidence of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates use of Sorafenib/TACE or patient at high risk from treatment&#xD;
             complications&#xD;
&#xD;
          -  Other severe concomitant disease that may reduce life expectancy&#xD;
&#xD;
          -  Risk of allergic reactions to the study drugs&#xD;
&#xD;
          -  Drug abuse or other physical, psychological , or social problems that may interfere&#xD;
             with the participation in the study or evaluation of study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinlong Song, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinlong Song, MD</last_name>
    <phone>+8653167626411</phone>
    <email>songjlmd@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenbo Shao, MD,Ph D</last_name>
    <phone>+8653167626412</phone>
    <email>shaowenbomd@gmai.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shandong Medical Imaging Research Institute</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Tang, MD</last_name>
      <phone>+8613964031909</phone>
      <email>tangjun7925032@163.com</email>
    </contact>
    <investigator>
      <last_name>Jun Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250114</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Caixia Li, MD</last_name>
      <phone>+8613505312972</phone>
      <email>Lilyshanda88@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Caixia Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital and Institute</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the Affiliated Hospital of Medical College Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zixiang Li, MD</last_name>
      <phone>+8618669739263</phone>
      <email>zixiangli@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Zixiang Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanbo Zheng, MD</last_name>
      <phone>+8613805356068</phone>
      <email>13805356068@163.com</email>
    </contact>
    <investigator>
      <last_name>Yanbo Zheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>May 21, 2012</last_update_submitted>
  <last_update_submitted_qc>May 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinlong Song</investigator_full_name>
    <investigator_title>Chief, Division of Interventiolal Therapy</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>transarterial chemoembolization</keyword>
  <keyword>sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Chlorotrianisene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

